Ajovy

Preventive Treatment of Migraine

Ajovy is specifically approved for the preventive treatment of migraine in adults. Unlike medications taken during an active headache, Ajovy is used on a regular schedule to help stop migraines from occurring.

Healthcare providers may prescribe this medication for different types of migraine patterns, including:

• Episodic migraine: This is defined as having fewer than 15 headache days per month.
• Chronic migraine: This involves having 15 or more headache days per month, where at least eight of those days meet the criteria for a migraine.

It is important to note that Ajovy is not used to treat an acute migraine attack that is already in progress. It does not provide immediate pain relief once a headache has started.

Mechanism of Action

Ajovy belongs to a class of medications called calcitonin gene-related peptide (CGRP) inhibitors. CGRP is a protein found in the brain and nervous system that plays a key role in the development of migraine attacks. During a migraine, levels of CGRP often increase, leading to inflammation and the widening of blood vessels in the brain, which causes pain.

Ajovy works by targeting and binding to the CGRP protein itself. By attaching to this protein, the medication prevents CGRP from binding to its receptors. This action helps to:

• Reduce the inflammation associated with migraines.
• Prevent the widening of blood vessels that contributes to headache pain.
• Block the transmission of pain signals in the brain.

Because Ajovy is a preventive treatment, it is designed to reduce the frequency and severity of migraine attacks over time. It is not intended to stop a migraine that has already begun.

Common Side Effects

The most frequent side effects of Ajovy occur at the site where the medication is injected. These reactions are usually mild to moderate and may include:

• Pain
• Redness
• Itching
• Swelling

Serious Side Effects

While rare, some people may experience serious allergic reactions. These reactions can occur immediately or several days after receiving an injection. Seek medical help right away if you notice symptoms such as:

• Severe rash or hives
• Swelling of the face, lips, tongue, or throat
• Difficulty breathing or wheezing
• Severe dizziness

If you experience any unusual symptoms or if injection site reactions persist or worsen, contact your healthcare provider.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis and angioedema, have been reported with the use of Ajovy. These reactions can occur within hours of administration, but in some cases, they may develop days or even up to one month after an injection.

Symptoms of a serious allergic reaction may include:

• Swelling of the face, mouth, tongue, or throat
• Difficulty breathing or wheezing
• Severe rash, hives, or intense itching

If a serious hypersensitivity reaction occurs, the medication is typically discontinued and appropriate medical treatment is initiated.

Contraindications

Ajovy is contraindicated in patients with a known history of serious hypersensitivity to fremanezumab-vfrm or any of the inactive ingredients in the formulation.

Monitoring

Because allergic reactions can be delayed, patients are often advised to monitor for signs of hypersensitivity for an extended period following each dose. If symptoms of a reaction appear, medical evaluation is necessary to determine if the medication should be stopped.

Pregnancy

It is not yet known if Ajovy will harm an unborn baby. There are no adequate or well-controlled studies of Ajovy use in pregnant women to determine drug-associated risks. In animal studies, no evidence of harm to the fetus was observed when the medication was administered during pregnancy. However, because Ajovy is a monoclonal antibody, it may be transferred from the mother to the fetus as the pregnancy progresses.

Breastfeeding

It is unknown whether Ajovy passes into human breast milk, how it affects milk production, or if it has any effect on a nursing infant. Because many medications can be excreted in human milk, you should consult your healthcare provider to weigh the benefits of breastfeeding against the potential risks to the child.

Consulting Your Doctor

If you are pregnant, planning to become pregnant, or breastfeeding, talk to your healthcare team before using this medication. They can help you evaluate your specific situation and determine the most appropriate course of treatment.

Available Forms

Ajovy is supplied as a sterile, preservative-free solution for injection under the skin (subcutaneous use). It is available in the following single-dose formats:

• Prefilled autoinjector: A device that automatically delivers the medication when pressed against the skin.
• Prefilled syringe: A manual syringe containing a single dose of the medication.

Each device is intended for one-time use only. Once the dose has been administered, the device should be disposed of in a sharps container.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Ajovy in September 2018. It is indicated for the preventive treatment of migraine in adults. The medication is used for patients with both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, of which at least eight are migraines).

Safety Monitoring and Labeling Updates

The FDA monitors the safety of Ajovy through the FDA Adverse Event Reporting System (FAERS). Following its initial approval, regulatory reviews identified potential signals of serious risks, which led to updates in the medication's safety labeling. These updates involve the risk of serious hypersensitivity reactions, including:

• Anaphylaxis (a severe, life-threatening allergic reaction)
• Angioedema (swelling of the face, mouth, or throat)
• Severe rash, hives, or itching

According to regulatory information, these allergic reactions can occur within hours of administration or may be delayed by up to one month after an injection. If a serious reaction occurs, the FDA recommends that the medication be discontinued and appropriate medical treatment be started.

Regulatory Status

Ajovy is a monoclonal antibody that belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists. It is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. The medication remains under standard post-marketing surveillance to monitor for any new safety concerns.

Factors Affecting Price

Several factors determine the out-of-pocket cost for Ajovy:

• Insurance Coverage: Costs are largely determined by your health insurance provider, including your plan's formulary, deductible, and copayment amounts.
• Pharmacy Selection: Different pharmacies may have different pricing or may be part of your insurance network.
• Dosing Frequency: Ajovy is available in monthly or quarterly dosing schedules, which may affect how often you pay for the medication.

Financial Support Options

Financial assistance may be available for eligible patients:

• Manufacturer Savings: A savings card may be available for individuals with commercial insurance to help lower copay costs.
• Patient Assistance: Programs may exist to help those without insurance or those who are underinsured access the medication.

Biosimilar Status

Ajovy is a brand-name biologic drug. There are currently no biosimilar versions available, which often means the price remains higher than medications with generic alternatives.